baber/WOPTO huggingface dataset:
Patent NZ-512422-A (NZ)
Title: Novel thyroid receptor ligands and method II
Inventor: LITTEN CHRIS
IPC: C07D295/13
Filed: 1999-12-23
Abstract: New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR'R'') or an acylsulphonamide (CONHSO2R') derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR'R''). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
Patent NZ-521795-A (NZ)
Title: An RFID inventory monitoring system
Inventor: KOH SOO KEONG
IPC: H04B1/59
Filed: 1998-06-08
Abstract: A monitoring system for a plurality of items, each with a radio frequency identification device mounted thereon and a corresponding unique identification code, being monitored by a plurality of radio frequency identification device readers located in the area to be supervised. A processing unit is coupled to a database containing information relating each item within the area and using the information from the readers, the database is updated accordingly, with a message to an operator of the system if an item is in an incorrect location.
Patent NZ-522142-A (NZ)
Title: Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
Inventor: BROWN WILLIAM
IPC: A61P25/02
Filed: 2001-03-30
Abstract: A compound of formula I for use in therapy such as pain management, gastrointestinal disorders, spinal injuries or disorders of the sympathetic nervous system.
Patent NZ-522996-A (NZ)
Title: Compositions and methods for body weight management
Inventor: JANDACEK RONALD JAMES
IPC: A23L33/20
Filed: 2001-06-21
Abstract: An oral composition that induces satiety in humans and animals comprising at least on satiety agent selected from the group consisting of non-glycerol esters of long chain fatty acids, such as lauric acid, lauroleic acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid, stearic acid, dihydroxystearic acid, oleic acid, ricinoleic acid, elaidic acid, linoleic acid, alpha-linolenic acid, dihomogamma-linolenic acid, eleostearic acid, licanic acid, arachidonic acid, arachidic acid, eicosenoic acid, eicosapentaenoic acid, behenic acid, erucic acid, docosahexaenoic acid or lignoceric acid, hydrolysable in the presence of gastro-intestinal enzymes, wherein said satiety agent releases in the stomach.
Patent NZ-524601-A (NZ)
Title: Method for treating erectile dysfunction and increasing libido in men
Inventor: DUDLEY ROBERT E
IPC: A61P25/28
Filed: 2001-08-29
Abstract: Disclosed is a method of improving the sexual performance, or increasing the libido of a male subject, comprising percutaneously delivering a pharmaceutically effective amount of a steroid selected from testosterone, androstenedione, androstenediol, dehydroepiandrosterone, prenolone and dihydrotesttosterone (DHT) in a hydroalcoholic gel to the subject using a pharmaceutical composition comprising the steroid, at least one C1-4alcohol, a penetration enhancer, a thickener and water. Also disclosed is a kit for treating erectile dysfunction, comprising a pharmaceutical useful for treating erectile dysfunction and a pharmaceutical composition for percutaneous administration comprising testosterone in a hydroalcoholic gel, including at least one C1-4alcohol, a penetration enhancer, a thickener and water.
Patent NZ-527860-A (NZ)
Title: Prion disinfection
Inventor: KRITZLER STEVEN
IPC: A01N63/50
Filed: 2002-01-31
Abstract: Methods of disinfecting a surface, suspension or solution contaminated with a PrPsc prion protein comprising treating the surface, suspension or solution simultaneously with a combination of one or more enzymes effective to cleave a prion protein to fragments having no-infective molecular weight and one or more agents selected to favor conformational unfolding of the PrPsc prion protein while not denaturing the enzymes, provided the method does not include the in vivo treatment of a human. Preferably the enzymes are proteinases and the surface from a medical or surgical instrument. Compositions are also described.
Patent NZ-528053-A (NZ)
Title: Container package with carrier and surrounding sleeve
Inventor: MARCO LESLIE S
IPC: B65D71/24
Filed: 2003-09-05
Abstract: A package (10) for containers (16) such as beverage bottles and cans includes an integral plastic carrier (12) with an array (22) of loops (52), one loop surrounding each container. A wide sleeve (14) surrounds the group (18) of containers held by the carrier. In a preferred arrangement, the carrier includes four rows of loops, with a handle (20) extending upwardly between the middle two rows. The loops are disposed within the sleeve. The sleeve is separate from the carrier.
Patent NZ-529654-A (NZ)
Title: CDK inhibiting pyrimidines, production thereof and their use as medicaments
Inventor: BRUMBY THOMAS
IPC: A61K31/5377
Filed: 2002-05-23
Abstract: Pyrimidine derivatives of formula (I) that are suitable use as inhibitors of the cyclin-dependent kinase (CDK) are disclosed, wherein R1, R2, X, A and B are as defined as in the specification. Also disclosed is the production of these CDK inhibitory pyrimidines as well as to their use as medicament in the treatment of various diseases.
Patent NZ-533139-A (NZ)
Title: Optical magnetron for high efficiency production of optical radiation, and 1/2 wavelength induced pi-mode
Inventor: SMALL JAMES G
IPC: H01J23/213
Filed: 2001-05-21
Abstract: A magnetron (22) comprises an anode (42) and a cathode (40) separated by a space (44) and connected with electrical contacts for applying a dc voltage and establishing an electric field across the space. The opening surface of the anode (42) has a plurality of resonant cavities, which define the space in which electrons emitted from the cathode (40) are influenced by the electric and magnetic fields to follow a path through the space (44). The anode (42) has a common resonator around its outer circumference which can be coupled to the resonant cavities to induce pi-mode operation.
Patent NZ-538307-A (NZ)
Title: Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
Inventor: BATTISTA KATHLEEN
IPC: C07D471/10
Filed: 2003-09-05
Abstract: Disclosed herein are hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of formula (I), wherein all variables are as defined in the specification. These compounds are useful in the treatment of disorders and conditions mediated by the ORL-1 (orphan opioid receptor) G-protein coupled receptor. More particularly, these compounds are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
Patent NZ-542067-A (NZ)
Title: Cooling device
Inventor: CLARKE DAVID CONRAD
Filed: 2005-09-29
Abstract: A cooling device which includes a cooling solution and an absorption means; such that the cooling solution includes one or more low boiling point alcohols, one or more cooling sensates and water; wherein at least part of the absorption means is configured to releasably absorb any cooling solution applied to it and in use allow contact between a user's skin and the cooling solution; and wherein said absorption means is a flexible garment configured to closely fit one or more body parts of the user.
Patent NZ-542688-A (NZ)
Title: Process for the staining of sperm
Inventor: ANZAR MUHAMMAD
IPC: A61K35/52
Filed: 2004-03-29
Abstract: Disclosed is a process for staining sperm cells, the process comprising forming a staining mixture containing intact viable sperm cells and a DNA selective fluorescent dye, and subjecting the staining mixture to a temperature in excess of 40 deg C without significantly impacting the viability of the stained cells. The process can allow differential sorting of sperm cells with X and Y chromosomes respectively.
Patent NZ-547701-A (NZ)
Title: Patient hose characteristics identified to ventilator by RFID
Inventor: SCHERMEIER OLAF
Filed: 2006-06-06
Abstract: The connectors on hoses 4 for delivering gases from ventilators to the patients are provided with electronic tags 5 such as radio frequency identification devices (RFIDs). As the hose is connected to or positioned adjacent to be connected to the associated connector of a ventilator 1 the information coded on the tag can be interrogated by the ventilator antenna 9 and reader/writer 6 to determine the compatibility of the ventilator with the hose and the values of settings to be set in the ventilator by the controller 7 for the treatment of the patient.
Patent NZ-548591-A (NZ)
Title: Multiple layer nonwoven products and methods for creating color schemes and for producing such products
Inventor: BRUNSON KEVIN K
IPC: B32B7/023
Filed: 2004-12-30
Abstract: A nonwoven product formed with at least two layers of nonwoven material comprising: the nonwoven material having a color scheme formed by differentially pigmenting associated fibers or filaments; at least one of the layers of nonwoven material having a color scheme different from the color scheme of one other layer of nonwoven material; and a color scheme being visible from at least a portion of the product and having a random appearance and being different from the respective color schemes of each layer. A method for forming the nonwoven product is also disclosed.
Patent NZ-563683-A (NZ)
Title: Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia
Inventor: SPEDDING MICHAEL
Filed: 2007-11-23
Abstract: Disclosed is a use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or one of its hydrates, crystalline forms and also addition salts with a pharmaceutically acceptable acid or base, in the manufacture of a medicament intended for the treatment of periventricular leukomalacia.
Patent NZ-569525-A (NZ)
Title: Holographic flexible tube laminate for packaging and method of making the same
Inventor: GUPTA SURESH VEDPRAKASH
IPC: B32B3/30
Filed: 2006-12-04
Abstract: Disclosed is a holographic flexible tube laminate for packaging and a method of making the same. A flexible laminate substrate applied with an adhesive layer has a metallised holographic embossed pattern transferred onto the adhesive layer. The holographic side of the laminate substrate is further printed and applied with a protective transparent material coating comprising ultraviolet curing varnish. The edges of the laminate substrate without the adhesive layer are lap joined by heat sealing to form the tube laminate.
Patent NZ-578505-A (NZ)
Title: Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
Inventor: JONES ROBERT M
IPC: A61K31/505
Filed: 2004-07-09
Abstract: Disclosed herein is the use of trisubstituted aryl and heteroaryl compounds of formula (I), wherein the substituents are as defined in the specification. Such compounds are useful in the treatment of conditions ameliorated by promoting beta-cell proliferation, condition ameliorated by inhibiting beta-cell death, idiopathic type 1 diabetes (Type 1 b), latent autoimmune diabetes in adults (LAD A), early-onset type 2 diabetes (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, coronary hear disease, ischemia, a transient ischemic event, stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, necrosis, apoptosis, post-prandial lipemia, a condition of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity, osteoporosis, hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, premenstrual syndrome, coronary hear disease, angina pectoris, thrombosis, atherosclerosis, vascular restenosis, hyperinsulinemia, impaired glucose metabolism, erectile dysfunction, a skin or connective tissue disorder, foot ulceration, ulcerative colitis, endothelial dysfunction, or impaired vascular compliance. (62) Divided Out of 544140
Patent NZ-580625-A (NZ)
Title: Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
Inventor: BESWICK MANDY CHRISTINE
IPC: C07D207/08
Filed: 2008-05-16
Abstract: Disclosed is a pyrrolidine substituted quinolone of formula (I) where the substituents are as disclosed in the specification. Examples of compounds of formula (I) are: 6-chloro-2-methyl-4-(3-phenylpyrrolidin-1-yl)quinoline; 6-benzyloxy-2-methyl-4-(3-phenylpyrrolidin-1-yl)quinoline; and 2-methyl-4-(3-phenylpyrrolidin-1-yl)-6-(pyridin-3-ylmethoxy)quinolone. Also disclosed is the process for preparing a compound of formula (I), a pharmaceutical composition comprising a compound of formula (I) the use of a compound of formula (I) for the manufacture of a medicament or as a steriliser or preservative and a combination product with an antimicrobial agent comprising a compound of formula (I). The medicament can be for treating or preventing microbial infections or for killing latent microorganisms.
Patent NZ-580743-A (NZ)
Title: A catheter having a vacuum skirt and an injection channel for pericardial access to the heart
Inventor: KASSAB GHASSAN S
IPC: A61M60/468
Filed: 2008-03-12
Abstract: 580743 Disclosed is an engagement catheter for use with a vacuum source for engaging a tissue. The engagement catheter has an elongated tube with a proximal end, a distal end, an outer wall positioned circumferentially along the length of the tube, and an inner wall positioned circumferentially along the length of the tube. The outer wall and the inner wall form a suction channel along the length of the tube between the outer wall and the inner wall. The elongated tube defines a delivery catheter lumen configured to receive a delivery catheter and an injection channel formed along a length of the elongated tube. The injection channel has at its distal end an at least one opening for administering a substance to a targeted tissue. The engagement catheter has a skirt which is operatively connected to the distal end of the tube. The skirt has a proximal end with a circumference that is similar to an outer circumference of the tube. The skirt has a distal end with a circumference that is larger than the circumference of the tube. The engagement catheter has a vacuum port in communication with the proximal end of the tube. The vacuum port is operatively connected to the suction channel and is capable of operative connection to the vacuum source. The engagement catheter has a suction port in communication with the suction channel at the distal end of the tube. The suction port is configured to allow the distal end of the skirt to removably engage a surface of a tissue such that the skirt is capable of forming a reversible seal with the surface of the tissue when a vacuum source is operatively attached to the vacuum port.
Patent NZ-584769-A (NZ)
Title: Anti-glypican-3 antibody having improved kinetics in plasma
Inventor: IGAWA TOMOYUKI
IPC: C12N1/19
Filed: 2008-09-26
Abstract: Disclosed is an anti-glypican 3 antibody which comprises a specific heavy chain variable region and a specific light chain variable region, as defined in the specification. Also disclosed is the use of said anti-glypican antibody for the treatment of cancer.
Patent NZ-585296-A (NZ)
Title: A modular aerofoil for a wind turbine and assembly method for said aerofoil
Inventor: GLENN BRIAN
IPC: F03D11/00
Filed: 2009-01-14
Abstract: Disclosed is a modular rotor blade for a power generating turbine that allows simple replacement of individual rotor blade sections in case of damage to or malfunction of a section. The modular rotor blade comprises at least two rotor blade sections (10, 11), wherein each rotor blade section comprises at least one connecting part (14, 16) having at least one conical opening (41, 42), the connecting parts of adjacent rotor blade sections rest against each other such that the conical openings of the connecting parts are aligned with each other and form a continuous conical connecting opening, receiving means for receiving tensioning means are arranged at the smaller diameter end of the conical connecting opening, a conical bolt (30) corresponding to the continuous conical connecting opening is arranged therein, and at least one tensioning means passing through the conical bolt (30) and tensioning the conical bolt against the receiving means.
Patent NZ-587371-A (NZ)
Title: The use of poly(I:C11-14U) for treating bacterial and protozoan infection
Inventor: CARTER WILLIAM A
IPC: A61K31/7105
Filed: 2009-02-17
Abstract: Disclosed is the use of poly(I:C11 -14U) in the manufacture of a medicament for the treatment of a subject with a bacterial infection or a protozoan infection. The medicament is formulated to initiate an innate immune response mediated only by Toll-Like Receptor 3 (TLR3), and activate TLR3 without activating other Toll-like receptors or RNA helicases, or without inducing an excessive amount of one or more pro-inflammatory cytokines.
Patent NZ-594030-A (NZ)
Title: Desulphurisation materials
Inventor: POTTER GAVIN
IPC: C10G25/00
Filed: 2009-02-25
Abstract: A process for the desulphurisation of a process fluid stream comprising contacting the stream, in the presence of hydrogen, with a particulate desulphurisation material comprising one or more nickel compounds, a zinc oxide support material, and one or more alkali metal compounds consisting of an oxide, carbonate or hydrogen carbonate of sodium, lithium, potassium or caesium wherein the nickel content of the material is in the range 0.3 to 10% by weight and the alkali metal content of the material is in the range 0.2 to 10% by weight.
Patent NZ-599497-A (NZ)
Title: Humanized antibodies to amyloid beta
Inventor: WATTS RYAN
IPC: A61K39/395
Filed: 2008-06-12
Abstract: Patent No. 599497 Disclosed is a chimeric antibody or fragment thereof, or humanized antibody or fragment thereof, capable of specifically binding beta amyloid, wherein the chimeric antibody or fragment thereof, or the humanized antibody or fragment thereof, comprises (i) the amino acid sequence of GFTFSSYGMS representing CDR1, the amino acid sequence of SINSNGGSTYYPDSVK representing CDR2 and the amino acid sequence of GDY representing CDR3 of the Heavy Chain Variable Region (HCVR), and (ii) the amino acid sequence of RSSQSLVYSNGDTYLH representing CDR1, the amino acid sequence of KVSNRFS or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution representing CDR2, and the amino acid sequence of SQSTHVPWT representing CDR3 of the Light Chain Variable Region (LCVR), wherein the chimeric antibody or fragment thereof, or the humanized antibody or fragment thereof comprises an IgG1 Fc region comprising an amino acid substitution at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the Fc region.
Patent NZ-600814-A (NZ)
Title: Stents having bioabsorbable layers
Inventor: MCCLAIN JAMES B
IPC: A61F2/82
Filed: 2012-06-22
Abstract: Disclosed is a method of preparing a device comprising a stent and a plurality of layers that form a laminate coating on said stent; said method comprising: (a) providing a stent; (b) discharging at least one pharmaceutical agent and/or at least one active biological agent in dry powder form through a first orifice; (c) forming a supercritical or near supercritical fluid solution comprising at least one supercritical fluid solvent and at least one polymer and discharging said supercritical or near supercritical fluid solution through a second orifice under conditions sufficient to form solid particles of the polymer; (d) depositing the polymer and pharmaceutical agent and/or active biological agent particles onto said substrate, wherein an electrical potential is maintained between the substrate and the polymer and pharmaceutical agent and/or active biological agent particles, thereby forming said coating; and (e) sintering said coating under conditions that do not substantially modify a morphology of said pharmaceutical agent and/or activity of said biological agent.
Patent NZ-601735-A (NZ)
Title: Antibody with binding specificity for Nedd4 protein for reducing influenza infectivity
Inventor: KINCH MICHAEL S
IPC: A61K39/395
Filed: 2010-01-06
Abstract: 601735 Disclosed is the use of an agent which inhibits the expression of Nedd4 protein in the manufacture of a medicament for reducing influenza infectivity in mammalian cells, wherein said agent is an antibody with binding specificity for Nedd4 protein.
Patent NZ-601985-A (NZ)
Title: Systems, methods, and apparatus for locating faults on an electrical distribution network
Inventor: KOLIWAD AJAY
IPC: G01D4/00
Filed: 2012-08-22
Abstract: Disclosed is a method for locating faults on an electrical distribution network. The method can include monitoring, by one or more smart meters, a plurality of voltage values associated with the electrical distribution network. When one or more of the plurality of monitored voltage values are detected to be less than or equal to a predetermined voltage for a specified time the meter stores at least a portion of monitored line voltage values and indicates a detected fault by transmitting one or more messages to a central station receiver. A fault location is determined based at least in part on the one or more messages and a topological and electrical model of the electrical distribution network.
Patent NZ-602359-A (NZ)
Title: Processing biomass
Inventor: MEDOFF MARSHALL
IPC: B29C48/395
Filed: 2009-11-13
Abstract: 602359 Disclosed is a method of making a processed biomass, the method comprising: providing a biomass feedstock; treating the biomass feedstock with radiation, sonication, pyrolysis, and/or oxidation to produce the processed biomass; subjecting the processed biomass to a screw extrusion process, and contacting the material with a microorganism having the ability to convert at least a portion of the material to a product.